MedPath

IMM60 and Pembrolizumab in Melanoma and NSCLC

Phase 1
Terminated
Conditions
Non-small Cell Lung Cancer
Melanoma
Interventions
Drug: IMM60
Drug: Pembrolizumab
Registration Number
NCT05709821
Lead Sponsor
iOx Therapeutics
Brief Summary

The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in participants with advanced melanoma or non-small cell lung cancer. There are two phases:

* Phase 1: This phase is designed to learn about the safety of IMM60 with or without pembrolizumab and to find a safe dose to test in Phase 2.

* Phase 2: This phase is designed to learn whether IMM60 + pembrolizumab improves progression-free survival at 12 months compared to pembrolizumab alone in participants with non-small cell lung cancer.

Detailed Description

This exploratory phase 1/phase 2 study is designed to establish a recommended phase 2 dose of IMM60 and provide preliminary estimates of safety and efficacy of IMM60 alone and in combination with pembrolizumab in participants with NSCLC and melanoma. In phase 1, initial safety will be assessed in a multiple dose escalation cohort for IMM60 alone, then for the IMM60 + pembrolizumab combination. Phase 2 of the study will recruit PD-1 pretreated melanoma participants and randomize PD-L1 \> 50% total NSCLC participants 2:1 to IMM60 + pembrolizumab vs pembrolizumab alone. There is an additional cohort of PD-L1 \< 1% NSCLC participants.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0 to 1

  • Adequate organ function

  • At least 1 lesion, not previously irradiated, that can be accurately measured on CT or MRI as defined by RECIST 1.1 criteria

  • NSCLC cohorts: Histologically confirmed diagnosis of stage IV NSCLC

  • NSCLC cohorts: Patients with adenocarcinoma histology must not have sensitizing epidermal growth factor receptor (EGFR) or ROS proto-oncogene 1 (ROS1) mutations or anaplastic lymphoma kinase (ALK) translocations

  • NSCLC cohorts: Participants in NSCLC arms must have a PD-L1 assessment (PD-L1 immuno-histochemistry (IHC) 22C3 pharmDx)

  • Melanoma cohorts: Unresectable stage III or IV, histologically confirmed diagnosis of cutaneous or unknown primary melanoma

  • Melanoma cohorts: B-type Raf proto-oncogene (BRAF) mutation status available

  • Male participants: Participant must agree to use contraception and refrain from sperm donation during the treatment period and for at least 120 days after the last dose of study intervention

  • Female participants: Participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP)
    2. A WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 6 months after the last dose of study intervention
Read More
Exclusion Criteria

  • Has the following cardiac conditions:

    1. Corrected QT interval (QTc) > 450 ms
    2. Uncontrolled hypertension with blood pressure (BP) > 160/100 despite treatment
    3. Class II or greater heart failure as defined by the New York Heart Association
    4. Myocardial infarction within 6 months or angina requiring nitrate therapy more than once a week

  • Another active malignancy within the past 2 years (Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder, or carcinoma in situ [e.g., breast carcinoma, cervical cancer in situ] that have undergone potentially curative therapy are not excluded. Also, prostate, breast, and neuroendocrine tumors that are stable on hormonal treatment for a period of 1 year or more without the need to adjust dose are not excluded.)

  • Has had an allogeneic tissue/solid organ transplant

  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable.

  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

  • Participants with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids (in dosing exceeding 10 mg daily of prednisone equivalent) or immunosuppressive agents.

  • Participants who are known to be serologically positive for Hepatitis B, Hepatitis C, or human immunodeficiency virus.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Phase 1 IMM60 dose escalation safety armIMM603 dose levels of IMM60 will be assessed (1, 3, 9 and 36 mg/m\^2 administered IV every 3 weeks for up to 6 cycles)
Phase 1 IMM60 + pembrolizumab combination safety armIMM60Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.
Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, IMM60 + pembrolizumab)IMM60Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.
Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, pembrolizumab monotherapy)PembrolizumabPembrolizumab 200 mg IV every 3 weeks for up to 35 cycles.
Phase 2 PD-L1 <1% NSCLC Cohort 2IMM60Participants will be treated with one cycle of IMM60 with a tumor biopsy before and after, to determine any changes in PD-L1 expression. After this one cycle, the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
Melanoma CohortIMM60IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
Phase 1 IMM60 + pembrolizumab combination safety armPembrolizumabPembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.
Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, IMM60 + pembrolizumab)PembrolizumabPembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.
Phase 2 PD-L1 <1% NSCLC Cohort 2PembrolizumabParticipants will be treated with one cycle of IMM60 with a tumor biopsy before and after, to determine any changes in PD-L1 expression. After this one cycle, the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
Primary Outcome Measures
NameTimeMethod
Phase 1 Co-Primary Objective - Identify Maximum Tolerated Dose (MTD)Assessed at the end of Cycle 1 for each patient (each Cycle is 28 days)

To confirm the maximum tolerated dose (MTD) of IMM60 alone and in combination with pembrolizumab, defined as the highest dose level at which \<2 out of 6 participants experience a dose-limiting toxicity

Phase 1 Co-Primary Objective - SafetyThrough Phase 1 completion, an average of 1 year

To characterize the safety of IMM60 alone and in combination with pembrolizumab, as assessed by the frequency of Grade 3 or higher treatment-related adverse events

Phase 2 Primary Objective - Progression-free Survival12 months after last participant enrolled

To compare the progression-free survival (PFS) rate at 12 months in the randomized arms comparing pembrolizumab alone versus IMM60 + pembrolizumab in patients with advanced PD-L1 ≥50% NSCLC

Secondary Outcome Measures
NameTimeMethod
Pharmacokinetics of IMM60 - Cmax (IMM60 arms only)During Cycles 1 and 3 (each Cycle is 28 days)

IMM60 maximal concentration (Cmax)

To characterize the safety of IMM60 alone or in combination with pembrolizumabThrough study completion, an average of 3 years

Frequency and severity of treatment-related adverse events (AEs)

To determine if IMM60 can restore sensitivity in PD-1 inhibitor-resistant melanoma (phase 2)12 months after last participant enrolled

Objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 in melanoma patients who have progressed on PD-1, and have added IMM60

Pharmacokinetics of IMM60 - AUC (IMM60 arms only)During Cycles 1 and 3 (each Cycle is 28 days)

IMM60 area under the curve (AUC)

Objective Response Rate (ORR)12 months after last participant enrolled

ORR is to be reported as the proportion of patients who have a Complete Response or Partial Response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1

To determine if IMM60 can sensitize patients with programmed death-ligand 1 (PD-L1) <1% NSCLC to PD-1 inhibition12 months after last participant enrolled

Objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 in PDL1 \<1% NSCLC patients who receive IMM60 + pembrolizumab

To assess the ability of IMM60 to convert PD-L1 negative patients to PD-L1 positive12 months after last participant enrolled

Percent of PD-L1 negative (\<1%) NSCLC tumors that increase PD-L1 gene expression following treatment with IMM60

Trial Locations

Locations (14)

Rutgers, The State University of New Jersey - Robert Wood Johnson Medical School - The Cancer Institute of New Jersey (CINJ)

🇺🇸

New Brunswick, New Jersey, United States

Next VA

🇺🇸

Fairfax, Virginia, United States

Hospital Xeral Álvaro Cunqueiro

🇪🇸

Vigo, Pontevedra, Spain

Hospital de La Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

H. Clínico de Valencia

🇪🇸

Valencia, Spain

Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol

🇪🇸

Badalona, Barcelona, Spain

Complexo Hospitalario Universitario A Coruña

🇪🇸

A Coruña, Galicia, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Regional Universitario de Málaga

🇪🇸

Málaga, Spain

Hospital Universitario Virgen De La Macarena

🇪🇸

Sevilla, Spain

Nottingham University Hospital - Oncology

🇬🇧

Nottingham, United Kingdom

USC Norris Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

Dana-Farber Cancer Institute - Medicine

🇺🇸

Boston, Massachusetts, United States

Henry Ford Hospital - Internal Medicine

🇺🇸

Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy